Global WholeHealth Partners Corp. (OTC: GWHP) Offers an Antibody IgG/IgM Test Capable of Detecting the South Africa Strain (B.1.351) and the U.K. Strain (B.1.1.7), of COVID 19 SARS 2
Global WholeHealth Partners Corp. (OTC: GWHP) provides a wide range of COVID-19 testing options, including an Antibody IgG/IgM test effective against various SARS-CoV-2 strains. With President Biden's push for enhanced testing through the Defense Production Act, GWHP aims to improve testing capabilities amid the ongoing pandemic. The company acknowledges the urgency for quicker testing solutions that can yield results in minutes, enhancing public health response. With 56 FDA-approved products and a capacity to produce up to 1 million tests daily, GWHP is positioned to meet the increasing global demand for rapid COVID-19 diagnostics.
- Wide range of COVID-19 tests, including FDA-authorized Point of Care tests.
- Capacity to produce up to 1 million tests per day.
- 56 FDA-approved products in the diagnostics sector.
- Increased market demand due to ongoing pandemic and need for rapid testing.
- Potential regulatory challenges with pending EUAs for new products.
- Intense competition from larger multinational companies in the medical device industry.
- Risk of supply chain disruptions due to reliance on single suppliers for certain components.
- Need for additional capital to meet future business requirements, which may be costly or dilutive.
Global WholeHealth Partners Corp. (OTC: GWHP) offers one of the largest line of COVID 19 tests.
San Clemente, CA, Feb. 10, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Global WholeHealth Partners Corp. (OTC: GWHP) offers one of the largest line of COVID 19 tests. Global WholeHealth Partners Corp (OTC: GWHP) offers an Antibody IgG/IgM test capable of detecting all the current identified SARS-CoV-2 viruses. The strains identified in the United Kingdom (B.1.1.7), South Africa (B.1.351), and Brazil (P.1) contain multiple mutations, most reflected in the S gene, which encodes the spike protein. Global understands the need to be ahead of the virus to conquer the virus.
“This is a wartime undertaking,” President Biden said. “Today, I’m signing executive action to use the Defense Production Act and all other available authorities to direct all federal agencies and private entities to accelerate the making of everything that’s needed to protect, test, vaccinate, and take care of our people.” https://philadelphia.cbslocal.com/2021/01/21/president-joe-biden-country-at-war-coronavirus/
Under Mr. Strongo’s direction, Global is following the President and his leadership and is making a war on COVID. To conquer COVID and win this war, Global must keep up the research and development of tests.
Mr. Strongo states, “Global continues to do research on all new strains of the COVID-19 virus to make sure the tests we offer are a useful and reliable diagnostic test."
Charles Strongo, CEO of Global WholeHealth Partners Corp, comments on https://www.cbsnews.com/news/covid-death-toll-united-states-expected-500k-february/ regarding the potential of 500,000 deaths by mid-February, as stated by the incoming director of the Centers for Disease Control. Mr. Strongo states that “the statement about the death toll reaching 500,000 is staggering, and it is our responsibility to be tested and to follow the rules of the CDC. We must keep testing, wearing masks and following the rules of social distancing, as directed by the CDC. We can defeat this virus. We must not take it lightly. It has killed thousands.”
The market is growing because of the outbreak of the coronavirus (SARS CoV-2) pandemic, which has increased the demand for rapid testing across the world. As the number of people suffering from the viral infection increases, the demand for rapid testing, which allows detecting the virus quickly, is growing. The adoption of a population-wide testing approach, which includes household, individual testing, is one of the trends influencing the demand for Covid-19 diagnostics kits. The shift from symptomatic testing to mass testing in developed countries is another major factor affecting the market.
Global WholeHealth Partners recognizes that there is a crucial need for faster testing and faster results when it comes to fighting the COVID. Global WholeHealth Partners knows that the quicker the test results can be reviewed by a Front-Line Healthcare Worker, the quicker we can stop the spread of this disease.
With results in minutes versus hours or days with other diagnostic kits, the more lives that can be saved with the only FDA authorized COVID-19 POC serology Point of Care Test. With the new fingerstick test, healthcare providers can prick a patient’s finger and get results in minutes without having to wait for venous blood. Global WholeHealth Partners will be able to distribute these tests to more urgent cares, hospitals, and – to help curb the spread of CoViD19 SARS2.
As a third surge of the coronavirus threatens much of the United States, public health experts across the country say there still aren’t enough tests available to keep the virus under control.
About 30 million Covid-19 tests are given every month, according to estimates from The Atlantic magazine’s Covid Tracking Project. But studies have found that the U.S. would need millions more — 193 million a month, according to one report — to be effective.
The USA has the largest number of Covid-19 cases in the world and there is concern that this next wave of infections will be worse than the previous. Global WholeHealth Partners, Corp. is confident that its Covid-19 Rapid Test can make a difference through assisting companies, staff, and public places where transmission may occur with a reliable, accurate, and fast Rapid Test.
Global WholeHealth Partners Corp. provides cutting edge technology using In-vitro Diagnostic (IVD) Real-Time PCR Machines for detection of SARS-CoV-2 IgM/IgG antibodies in human serum, plasma, or whole blood. It has led the fight against vector borne terminal diseases such as Ebola, ZIKA, Dengue, Malaria, Influenza and Tuberculosis, Corona Viruses, and among other vector borne diseases. The company was founded on March 7, 2013 and is headquartered in San Clemente, CA.
GWHP develops, manufactures, and markets in vitro diagnostic (IVD) tests for OTC, or consumer-use as well as professional rapid diagnostic point-of-care (POC) test kits for hospitals, physicians’ offices, and medical clinics in the US and abroad. Notably, GWHP offers a CE Mark for its high quality, rapid antibody test for COVID-19 and an EUA filing with the FDA is pending approval. In the interim, the US Navy in California has been using the test during 2Q20 and the Company has the capacity to deliver hundreds of thousands of tests, ramping up to 1 million per day. Currently, the Company has 56 products FDA approved and many are Approved for OTC use, and 9 POC products approved by the FDA.
Disclaimer:
The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time.
Media Contact:
Name: Charles Strongo,
CEO, Global WholeHealth Partners Corp.
Email: investors@gwhpcorp.com
Forward-Looking Statements
This press release contains "forward-looking statements.” Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
FAQ
What types of COVID-19 tests does GWHP offer?
How many COVID-19 tests can GWHP produce per day?
What is the significance of the Defense Production Act for GWHP?
How does GWHP's testing technology work?
What is the market outlook for COVID-19 diagnostics according to GWHP?
